<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Newamsterdam Pharma Company N.v. Ordinary Shares — News on 6ix</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares</link>
<description>Latest news and press releases for Newamsterdam Pharma Company N.v. Ordinary Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/newamsterdam-pharma-company-nv-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a06478dffbe2df108de2.webp</url>
<title>Newamsterdam Pharma Company N.v. Ordinary Shares</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares</link>
</image>
<item>
<title>NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and M</description>
</item>
<item>
<title>NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-announces-three-presentations-at-the-2026-american-college-of-cardiology-annual-scientific-session</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-announces-three-presentations-at-the-2026-american-college-of-cardiology-annual-scientific-session</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 18 Feb 2026 12:00:00 GMT</pubDate>
<description>-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- -- $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 -- NAARDEN, the Netherlands and MIAM</description>
</item>
<item>
<title>NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-guggenheim-emerging-outlook-biotech-summit-2026-02-04</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-guggenheim-emerging-outlook-biotech-summit-2026-02-04</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-highlights-2025-achievements-and-outlines-2026-strategic</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-highlights-2025-achievements-and-outlines-2026-strategic</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in</description>
</item>
<item>
<title>NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>NAARDEN, the Netherlands and MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-investor-conferences-december-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-investor-conferences-december-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-provides-corporate-update-and-reports-third-quarter-financial</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-provides-corporate-update-and-reports-third-quarter-financial</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>– Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from</description>
</item>
<item>
<title>NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-medical-meeting-and-investor-conferences-0</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-medical-meeting-and-investor-conferences-0</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/caristo-chosen-leading-pharma-company-worldwide-imaging-core-lab-measure-coronary</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/caristo-chosen-leading-pharma-company-worldwide-imaging-core-lab-measure-coronary</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and</description>
</item>
<item>
<title>NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-stifel-2025-virtual-cardiometabolic-forum-2025-09-24</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-stifel-2025-virtual-cardiometabolic-forum-2025-09-24</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-medical-meeting-and-investor-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-medical-meeting-and-investor-conferences-1</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/piramal-pharma-solutions-and-newamsterdam-pharma-invest-dedicated-suite-enhance-oral</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/piramal-pharma-solutions-and-newamsterdam-pharma-invest-dedicated-suite-enhance-oral</guid>
<pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
<description>The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to</description>
</item>
<item>
<title>NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-announces-acceptance-marketing-authorization-applications-review</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-announces-acceptance-marketing-authorization-applications-review</guid>
<pubDate>Mon, 18 Aug 2025 04:00:00 GMT</pubDate>
<description>-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment</description>
</item>
<item>
<title>NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-presents-positive-data-broadway-trial-demonstrating-statistically</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-presents-positive-data-broadway-trial-demonstrating-statistically</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in</description>
</item>
<item>
<title>NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-alzheimers-biomarker-data-broadway-trial-aaic-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-alzheimers-biomarker-data-broadway-trial-aaic-2025-2025</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-announces-positive-topline-alzheimers-disease-data-broadway</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-announces-positive-topline-alzheimers-disease-data-broadway</guid>
<pubDate>Mon, 09 Jun 2025 04:00:00 GMT</pubDate>
<description>-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome</description>
</item>
<item>
<title>NewAmsterdam Pharma to Host R&D Day on June 11, 2025</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-host-rd-day-june-11-2025-2025-06-05</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-host-rd-day-june-11-2025-2025-06-05</guid>
<pubDate>Thu, 05 Jun 2025 04:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-investor-conferences-june-2025-05-27</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-participate-upcoming-investor-conferences-june-2025-05-27</guid>
<pubDate>Tue, 27 May 2025 04:00:00 GMT</pubDate>
<description>NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
<item>
<title>NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference</title>
<link>https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-2025-rbccm-global-healthcare-conference-2025-05-14</link>
<guid isPermaLink="true">https://6ix.com/company/newamsterdam-pharma-company-nv-ordinary-shares/news/newamsterdam-pharma-present-2025-rbccm-global-healthcare-conference-2025-05-14</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a</description>
</item>
</channel>
</rss>